150
Participants
Start Date
April 17, 2019
Primary Completion Date
November 26, 2020
Study Completion Date
August 8, 2024
Bulevirtide
Administered via SC injections
New York University School of Medicine, an administrative unit of New York University, an education corporation, New York
Cornell University Well Madical College, New York
Universitätsklinikum Essen (AoR), Klinik für Gastroenterologie und Hepatologie, Essen
Universitätsklinikum Frankfurt Medizinische Klinik 1, Frankfurt am Main
Universitätsklinikum Hamburg-Eppendorf, Hamburg
Medizinische Hochschule Hannover, Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Hanover
Heidelberg University Hospital, Departament of Gastroenterology, Infectious Diseases, Intoxication, Heidelberg
Division of Gastroenterology and Hepatology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan
Università di Modena e Reggio Emilia- Ospedale Civile S., Modena
U.O. Epatologia - Azienda Ospedaliero Universitaria Pisana, Pisa
"State Budgetary Educational Institution of Higher Professional Education South Ural State Medical University of the Ministry of Healthcare of the Russian Federation", Chelyabinsk
Specialized clinical Infectious diseases Hospital, Krasnodar
"Federal Budget Institution of Science Central Research Institute of Epidemiology of The Federal Service on Customers' Rights Protection and Human Well-being Surveillance", Moscow
Federal State Budgetary Institution National Research Medical Center for Phthisiopulmonology and Infectious Diseases of the Ministry of Health of the Russian Federation, Moscow
"LLCClinic of Modern Medicine", Moscow
Moscow Regional Scientific and Research Clinical Institute, Moscow
"LLC Medical Company Hepatolog", Samara
Stavropol Regional Hospital, Stavropol
Karolinska University Hospital Huddinge, Dept of Infectious Diseases, Stockholm
Lead Sponsor
Gilead Sciences
INDUSTRY